Clinical Trial Update: Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial CRY-04 evaluating dose-dense chemotherapy with rituximab for young patients with high-risk diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Nordic Lymphoma Group | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED